|
1
|
Schnabel RB, Yin X, Gona P, Larson MG,
Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW,
Ellinor PT, et al: 50 Year trends in atrial fibrillation
prevalence, incidence, risk factors, and mortality in the
Framingham heart study: A cohort study. Lancet. 386:154–162.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Benjamin EJ, Muntner P, Alonso A,
Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR,
Cheng S, Das SR, et al: Heart disease and stroke statistics-2019
update: A report from the american heart association. Circulation.
139:e56–e528. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kornej J, Börschel CS, Benjamin EJ and
Schnabel RB: Epidemiology of atrial fibrillation in the 21st
century: Novel methods and new insights. Circ Res. 127:4–20.
2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Staerk L, Sherer JA, Ko D, Benjamin EJ and
Helm RH: Atrial fibrillation: Epidemiology, pathophysiology, and
clinical outcomes. Circ Res. 120:1501–1517. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mark DB, Anstrom KJ, Sheng S, Piccini JP,
Baloch KN, Monahan KH, Daniels MR, Bahnson TD, Poole JE, Rosenberg
Y, et al: Effect of catheter ablation vs medical therapy on quality
of life among patients with atrial fibrillation: the CABANA
randomized clinical trial. JAMA. 321:1275–1285. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Packer DL, Mark DB, Robb RA, Monahan KH,
Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N,
Mitchell LB, et al: Effect of catheter ablation vs antiarrhythmic
drug therapy on mortality, stroke, bleeding, and cardiac arrest
among patients with atrial fibrillation: The CABANA randomized
clinical trial. JAMA. 321:1261–1274. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Prabhu S, Taylor AJ, Costello BT, Kaye DM,
McLellan AJA, Voskoboinik A, Sugumar H, Lockwood SM, Stokes MB,
Pathik B, et al: Catheter ablation versus medical rate control in
atrial fibrillation and systolic dysfunction: The CAMERA-MRI study.
J Am Coll Cardiol. 70:1949–1961. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Marrouche NF, Brachmann J, Andresen D,
Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders
P, Proff J, et al: Catheter ablation for atrial fibrillation with
heart failure. N Engl J Med. 378:417–427. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Calkins H, Hindricks G, Cappato R, Kim YH,
Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, et al:
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on
catheter and surgical ablation of atrial fibrillation. Europace.
20:e1–e160. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
January CT, Wann LS, Alpert JS, Calkins H,
Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD,
Field ME, et al: 2014 AHA/ACC/HRS guideline for the management of
patients with atrial fibrillation: A report of the American college
of cardiology/American heart association task force on practice
guidelines and the heart rhythm society. J Am Coll Cardiol.
64:e1–e76. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kirchhof P, Benussi S, Kotecha D, Ahlsson
A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks
J, et al: 2016 ESC guidelines for the management of atrial
fibrillation developed in collaboration with EACTS. Eur J
Cardiothorac Surg. 50:e1–e88. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Camm AJ, Kirchhof P, Lip GY, Schotten U,
Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G,
Prendergast B, et al: Guidelines for the management of atrial
fibrillation: The task force for the management of atrial
fibrillation of the European society of cardiology (ESC). Europace.
12:1360–1420. 2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Camm AJ, Lip GY, De Caterina R, Savelieva
I, Atar D, Hohnloser SH, Hindricks G and Kirchhof P: ESC Committee
for Practice Guidelines (CPG). 2012 Focused update of the ESC
guidelines for the management of atrial fibrillation: An update of
the 2010 ESC guidelines for the management of atrial fibrillation.
Developed with the special contribution of the European heart
rhythm association. Eur Heart J. 33:2719–2747. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wyse DG, Waldo AL, DiMarco JP, Domanski
MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC,
Dalquist JE, et al: A comparison of rate control and rhythm control
in patients with atrial fibrillation. N Engl J Med. 347:1825–1833.
2002.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Van Gelder IC, Hagens VE, Bosker HA,
Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ,
Tijssen JG, et al: A comparison of rate control and rhythm control
in patients with recurrent persistent atrial fibrillation. N Engl J
Med. 347:1834–1840. 2002.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Carlsson J, Miketic S, Windeler J, Cuneo
A, Haun S, Micus S, Walter S and Tebbe U: STAF Investigators.
Randomized trial of rate-control versus rhythm-control in
persistent atrial fibrillation: The strategies of treatment of
atrial fibrillation (STAF) study. J Am Coll Cardiol. 41:1690–1696.
2003.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kirchhof P, Camm AJ, Goette A, Brandes A,
Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM,
et al: Early rhythm-control therapy in patients with atrial
fibrillation. N Engl J Med. 383:1305–1316. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
January CT, Wann LS, Calkins H, Chen LY,
Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME,
Furie KL, et al: 2019 AHA/ACC/HRS focused update of the 2014
AHA/ACC/HRS guideline for the management of patients with atrial
fibrillation: A report of the American College of
cardiology/american heart association task force on clinical
practice guidelines and the heart rhythm society in collaboration
with the society of thoracic surgeons. Circulation. 140:e125–e151.
2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hindricks G, Potpara T, Dagres N, Arbelo
E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA,
Dilaveris PE, et al: 2020 ESC guidelines for the diagnosis and
management of atrial fibrillation developed in collaboration with
the European association for cardio-thoracic surgery (EACTS): The
task force for the diagnosis and management of atrial fibrillation
of the European Society of Cardiology (ESC) developed with the
special contribution of the European heart rhythm association
(EHRA) of the ESC. Eur Heart J. 42:373–498. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Doyle JF and Ho KM: Benefits and risks of
long-term amiodarone therapy for persistent atrial fibrillation: A
meta-analysis. Mayo Clin Proc. 84:234–242. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Roy D, Talajic M, Dorian P, Connolly S,
Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagné P, et al:
Amiodarone to prevent recurrence of atrial fibrillation. Canadian
trial of atrial fibrillation investigators. N Engl J Med.
342:913–920. 2000.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Khan AR, Khan S, Sheikh MA, Khuder S,
Grubb B and Moukarbel GV: Catheter ablation and antiarrhythmic drug
therapy as first- or second-line therapy in the management of
atrial fibrillation: Systematic review and meta-analysis. Circ
Arrhythm Electrophysiol. 7:853–860. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Andrade JG: Ablation as first-line therapy
for atrial fibrillation. Eur Cardiol. 18(e46)2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Turagam MK, Musikantow D, Whang W, Koruth
JS, Miller MA, Langan MN, Sofi A, Choudry S, Dukkipati SR and Reddy
VY: Assessment of catheter ablation or antiarrhythmic drugs for
first-line therapy of atrial fibrillation: A meta-analysis of
randomized clinical trials. JAMA Cardiol. 6:697–705.
2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Joglar JA, Chung MK, Armbruster AL,
Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger
ZD, Gopinathannair R, et al: 2023 ACC/AHA/ACCP/HRS guideline for
the diagnosis and management of atrial fibrillation: A report of
the american college of cardiology/American heart association joint
committee on clinical practice guidelines. Circulation.
149:e1–e156. 2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hocini M, Sanders P, Deisenhofer I, Jaïs
P, Hsu LF, Scavée C, Weerasoriya R, Raybaud F, Macle L, Shah DC, et
al: Reverse remodeling of sinus node function after catheter
ablation of atrial fibrillation in patients with prolonged sinus
pauses. Circulation. 108:1172–1175. 2003.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chen YW, Bai R, Lin T, Salim M, Sang CH,
Long DY, Yu RH, Tang RB, Guo XY, Yan XL, et al: Pacing or ablation:
Which is better for paroxysmal atrial fibrillation-related
tachycardia-bradycardia syndrome? Pacing Clin Electrophysiol.
37:403–411. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Inada K, Yamane T, Tokutake K, Yokoyama K,
Mishima T, Hioki M, Narui R, Ito K, Tanigawa S, Yamashita S, et al:
The role of successful catheter ablation in patients with
paroxysmal atrial fibrillation and prolonged sinus pauses: Outcome
during a 5-year follow-up. Europace. 16:208–213. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Koopman P, Nuyens D, Garweg C, La Gerche
A, De Buck S, Van Casteren L, Alzand B, Willems R and Heidbuchel H:
Efficacy of radiofrequency catheter ablation in athletes with
atrial fibrillation. Europace. 13:1386–1393. 2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Furlanello F, Lupo P, Pittalis M, Foresti
S, Vitali-Serdoz L, Francia P, De Ambroggi G, Ferrero P, Nardi S,
Inama G, et al: Radiofrequency catheter ablation of atrial
fibrillation in athletes referred for disabling symptoms preventing
usual training schedule and sport competition. J Cardiovasc
Electrophysiol. 19:457–462. 2008.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Pathak RK, Elliott A, Middeldorp ME,
Meredith M, Mehta AB, Mahajan R, Hendriks JM, Twomey D, Kalman JM,
Abhayaratna WP, et al: Impact of CARDIOrespiratory fitness on
arrhythmia recurrence in obese individuals with atrial
fibrillation: The CARDIO-FIT study. J Am Coll Cardiol. 66:985–996.
2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Deshpande R, AlKhadra Y, Singanallur P,
Botchway A and Labedi M: Outcomes of catheter ablation versus
antiarrhythmic therapy in patients with atrial fibrillation: A
systematic review and meta-analysis. J Interv Card Electrophysiol.
65:773–802. 2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Deedwania PC and Lardizabal JA: Atrial
fibrillation in heart failure: A comprehensive review. Am J Med.
123:198–204. 2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Nerheim P, Birger-Botkin S, Piracha L and
Olshansky B: Heart failure and sudden death in patients with
tachycardia-induced cardiomyopathy and recurrent tachycardia.
Circulation. 110:247–252. 2004.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Raymond RJ, Lee AJ, Messineo FC, Manning
WJ and Silverman DI: Cardiac performance early after cardioversion
from atrial fibrillation. Am Heart J. 136:435–442. 1998.PubMed/NCBI View Article : Google Scholar
|
|
36
|
January CT, Wann LS, Calkins H, Chen LY,
Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME,
Furie KL, et al: 2019 AHA/ACC/HRS focused update of the 2014
AHA/ACC/HRS guideline for the management of patients with atrial
fibrillation: A report of the American college of
cardiology/American heart association task force on clinical
practice guidelines and the heart rhythm society. J Am Coll
Cardiol. 74:104–132. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Şaylık F, Çınar T, Akbulut T and Hayıroğlu
Mİ: Comparison of catheter ablation and medical therapy for atrial
fibrillation in heart failure patients: A meta-analysis of
randomized controlled trials. Heart Lung. 57:69–74. 2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Chang TY, Chao TF, Lin CY, Lin YJ, Chang
SL, Lo LW, Hu YF, Chung FP and Chen SA: Catheter ablation of atrial
fibrillation in heart failure with impaired systolic function: An
updated meta-analysis of randomized controlled trials. J Chin Med
Assoc. 86:11–18. 2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zafrir B, Lund LH, Laroche C, Ruschitzka
F, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Seferovic
PM, Maggioni AP, et al: Prognostic implications of atrial
fibrillation in heart failure with reduced, mid-range, and
preserved ejection fraction: A report from 14 964 patient in the
European society of cardiology heart failure long-term registry.
Eur Heart J. 39:4277–4284. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Sartipy U, Dahlström U, Fu M and Lund LH:
Atrial fibrillation in heart failure with preserved, mid-range, and
reduced ejection fraction. JACC Heart Fail. 5:565–574.
2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Gu G, Wu J, Gao X, Liu M, Jin C and Xu Y:
Catheter ablation of atrial fibrillation in patients with heart
failure and preserved ejection fraction: A meta-analysis. Clin
Cardiol. 45:786–793. 2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Kawamura I, Aikawa T, Yokoyama Y, Takagi H
and Kuno T: Catheter ablation for atrial fibrillation in elderly
patients: Systematic review and a meta-analysis. Pacing Clin
Electrophysiol. 45:59–71. 2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Lee WC, Wu PJ, Chen HC, Fang HY, Liu PY
and Chen MC: Efficacy and safety of ablation for symptomatic atrial
fibrillation in elderly patients: A meta-analysis. Front Cardiovasc
Med. 8(734204)2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Li F, Zhang L, Wu LD, Zhang ZY, Liu HH,
Zhang ZY, Zhang J, Qian LL and Wang RX: Do elderly patients with
atrial fibrillation have comparable ablation outcomes compared to
younger ones? Evidence from pooled clinical studies. J Clin Med.
11(4468)2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Spragg DD, Dalal D, Cheema A, Scherr D,
Chilukuri K, Cheng A, Henrikson CA, Marine JE, Berger RD, Dong J
and Calkins H: Complications of catheter ablation for atrial
fibrillation: Incidence and predictors. J Cardiovasc
Electrophysiol. 19:627–631. 2008.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Leong-Sit P, Zado E, Callans DJ, Garcia F,
Lin D, Dixit S, Bala R, Riley MP, Hutchinson MD, Cooper J, et al:
Efficacy and risk of atrial fibrillation ablation before 45 years
of age. Circ Arrhythm Electrophysiol. 3:452–457. 2010.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Kalman JM, Sanders P, Rosso R and Calkins
H: Should we perform catheter ablation for asymptomatic atrial
fibrillation? Circulation. 136:490–499. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Rienstra M, Vermond RA, Crijns HJ, Tijssen
JG and Van Gelder IC: RACE Investigators. Asymptomatic persistent
atrial fibrillation and outcome: Results of the RACE study. Heart
Rhythm. 11:939–945. 2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Boriani G, Laroche C, Diemberger I,
Fantecchi E, Popescu MI, Rasmussen LH, Sinagra G, Petrescu L,
Tavazzi L, Maggioni AP and Lip GYH: Asymptomatic atrial
fibrillation: Clinical correlates, management, and outcomes in the
EORP-AF pilot general registry. Am J Med. 128:509–518.e2.
2015.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Santhanakrishnan R, Wang N, Larson MG,
Magnani JW, McManus DD, Lubitz SA, Ellinor PT, Cheng S, Vasan RS,
Lee DS, et al: Atrial fibrillation begets heart failure and vice
versa: Temporal associations and differences in preserved versus
reduced ejection fraction. Circulation. 133:484–492.
2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Mohanty S, Santangeli P, Mohanty P, Di
Biase L, Holcomb S, Trivedi C, Bai R, Burkhardt D, Hongo R, Hao S,
et al: Catheter ablation of asymptomatic longstanding persistent
atrial fibrillation: impact on quality of life, exercise
performance, arrhythmia perception, and arrhythmia-free survival. J
Cardiovasc Electrophysiol. 25:1057–1064. 2014.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Wu L, Lu Y, Zheng L, Qiao YU, Chen G, Ding
L, Hou B, Sun W, Liew R, Zhang S and Yao Y: Comparison of
radiofrequency catheter ablation between asymptomatic and
symptomatic persistent atrial fibrillation: A propensity score
matched analysis. J Cardiovasc Electrophysiol. 27:531–535.
2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Pak M, Kobori A, Shizuta S, Sasaki Y,
Toyota T, Yoshizawa T, Inoue K, Kaitani K, Kurotobi T, Morishima I,
et al: The impact of catheter ablation for patients with
asymptomatic atrial fibrillation: Subanalysis of kansai plus atrial
fibrillation (kpaf) registry. Eur Heart J. 41 (Suppl
2)(ehaa946.0442)2020.
|
|
54
|
Kawaji T, Shizuta S, Tanaka M, Nishiwaki
S, Aizawa T, Yamagami S, Komasa A, Yoshizawa T, Kato M, Yokomatsu
T, et al: Prognostic impact of catheter ablation in patients with
asymptomatic atrial fibrillation. PLoS One.
17(e0279178)2022.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Corley SD, Epstein AE, DiMarco JP,
Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein
RC, Krahn AD, et al: Relationships between sinus rhythm, treatment,
and survival in the Atrial Fibrillation follow-up investigation of
rhythm management (AFFIRM) study. Circulation. 109:1509–1513.
2004.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Barra S, Baran J, Narayanan K, Boveda S,
Fynn S, Heck P, Grace A, Agarwal S, Primo J, Marijon E and
Providência R: Association of catheter ablation for atrial
fibrillation with mortality and stroke: A systematic review and
meta-analysis. Int J Cardiol. 266:136–142. 2018.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Barra S, Narayanan K, Boveda S, Primo J,
Gonçalves H, Baran J, Agarwal S, Marijon E and Providência R:
Atrial Fibrillation ablation and reduction of stroke events:
Understanding the paradoxical lack of evidence. Stroke.
50:2970–2976. 2019.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Mao YJ, Wang H, Chen JX and Huang PF:
Meta-analysis of medical management versus catheter ablation for
atrial fibrillation. Rev Cardiovasc Med. 21:419–432.
2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Shi LZ, Heng R, Liu SM and Leng FY: Effect
of catheter ablation versus antiarrhythmic drugs on atrial
fibrillation: A meta-analysis of randomized controlled trials. Exp
Ther Med. 10:816–822. 2015.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Freedman B, Martinez C, Katholing A and
Rietbrock S: Residual risk of stroke and death in
anticoagulant-treated patients with atrial fibrillation. JAMA
Cardiol. 1:366–368. 2016.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Balsam P, Tymińska A, Ozierański K,
Zaleska M, Żukowska K, Szepietowska K, Maciejewski K, Peller M,
Grabowski M, Lodziński P, et al: Randomized controlled clinical
trials versus real-life atrial fibrillation patients treated with
oral anticoagulants. Do we treat the same patients? Cardiol J.
27:590–599. 2020.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Camm AJ, Amarenco P, Haas S, Hess S,
Kirchhof P, Lambelet M, Bach M and Turpie AGG: Real-world vs
randomized trial outcomes in similar populations of
rivaroxaban-treated patients with non-valvular atrial fibrillation
in ROCKET AF and XANTUS. Europace. 21:421–427. 2019.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Ganesan AN, Shipp NJ, Brooks AG, Kuklik P,
Lau DH, Lim HS, Sullivan T, Roberts-Thomson KC and Sanders P:
Long-term outcomes of catheter ablation of atrial fibrillation: A
systematic review and meta-analysis. J Am Heart Assoc.
2(e004549)2013.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Gaita F, Caponi D, Scaglione M, Montefusco
A, Corleto A, Di Monte F, Coin D, Di Donna P and Giustetto C:
Long-term clinical results of 2 different ablation strategies in
patients with paroxysmal and persistent atrial fibrillation. Circ
Arrhythm Electrophysiol. 1:269–275. 2008.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Ouyang F, Tilz R, Chun J, Schmidt B,
Wissner E, Zerm T, Neven K, Köktürk B, Konstantinidou M, Metzner A,
et al: Long-term results of catheter ablation in paroxysmal atrial
fibrillation: Lessons from a 5-year follow-up. Circulation.
122:2368–2377. 2010.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Wijffels MC, Kirchhof CJ, Dorland R and
Allessie MA: Atrial fibrillation begets atrial fibrillation. A
study in awake chronically instrumented goats. Circulation.
92:1954–1968. 1995.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Wokhlu A, Monahan KH, Hodge DO, Asirvatham
SJ, Friedman PA, Munger TM, Bradley DJ, Bluhm CM, Haroldson JM and
Packer DL: Long-term quality of life after ablation of atrial
fibrillation the impact of recurrence, symptom relief, and placebo
effect. J Am Coll Cardiol. 55:2308–2316. 2010.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Ware JE, Snow KK, Kosinski M and Gandek B:
SF-36 Health Survey: Manual and Interpretation Guide. New England
Medical Center, The Health Institute, Boston, 1993.
|
|
69
|
Kirchhof P, Auricchio A, Bax J, Crijns H,
Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger
L, et al: Outcome parameters for trials in atrial fibrillation:
Executive summary. Eur Heart J. 28:2803–2817. 2007.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Reynolds MR, Ellis E and Zimetbaum P:
Quality of life in atrial fibrillation: Measurement tools and
impact of interventions. J Cardiovasc Electrophysiol. 19:762–768.
2008.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Jaïs P, Cauchemez B, Macle L, Daoud E,
Khairy P, Subbiah R, Hocini M, Extramiana F, Sacher F, Bordachar P,
et al: Catheter ablation versus antiarrhythmic drugs for atrial
fibrillation: The A4 study. Circulation. 118:2498–2505.
2008.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Wazni OM, Marrouche NF, Martin DO, Verma
A, Bhargava M, Saliba W, Bash D, Schweikert R, Brachmann J, Gunther
J, et al: Radiofrequency ablation vs antiarrhythmic drugs as
first-line treatment of symptomatic atrial fibrillation: A
randomized trial. JAMA. 293:2634–2640. 2005.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Cosedis Nielsen J, Johannessen A,
Raatikainen P, Hindricks G, Walfridsson H, Kongstad O, Pehrson S,
Englund A, Hartikainen J, Mortensen LS and Hansen PS:
Radiofrequency ablation as initial therapy in paroxysmal atrial
fibrillation. N Engl J Med. 367:1587–1595. 2012.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Morillo CA, Verma A, Connolly SJ, Kuck KH,
Nair GM, Champagne J, Sterns LD, Beresh H, Healey JS and Natale A:
RAAFT-2 Investigators. Radiofrequency ablation vs antiarrhythmic
drugs as first-line treatment of paroxysmal atrial fibrillation
(RAAFT-2): A randomized trial. JAMA. 311:692–700. 2014.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Walfridsson H, Walfridsson U, Nielsen JC,
Johannessen A, Raatikainen P, Janzon M, Levin LA, Aronsson M,
Hindricks G, Kongstad O, et al: Radiofrequency ablation as initial
therapy in paroxysmal atrial fibrillation: Results on
health-related quality of life and symptom burden. The MANTRA-PAF
trial. Europace. 17:215–221. 2015.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Maesen B, van der Heijden CAJ, Bidar E,
Vos R, Athanasiou T and Maessen JG: Patient-reported quality of
life after stand-alone and concomitant arrhythmia surgery: A
systematic review and meta-analysis. Interact Cardiovasc Thorac
Surg. 34:339–348. 2022.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Siontis KC, Ioannidis JPA, Katritsis GD,
Noseworthy PA, Packer DL, Hummel JD, Jais P, Krittayaphong R, Mont
L, Morillo CA, et al: Radiofrequency ablation versus antiarrhythmic
drug therapy for atrial fibrillation: Meta-analysis of quality of
life, morbidity, and mortality. JACC Clin Electrophysiol.
2:170–180. 2016.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Raine D, Langley P, Shepherd E, Lord S,
Murray S, Murray A and Bourke JP: Effect of catheter ablation on
quality of life in patients with atrial fibrillation and its
correlation with arrhythmia outcome. Open Heart.
2(e000302)2015.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Dagres N, Varounis C, Flevari P,
Piorkowski C, Bode K, Rallidis LS, Tsougos E, Leftheriotis D,
Sommer P, Hindricks G and Kremastinos DT: Mortality after catheter
ablation for atrial fibrillation compared with antiarrhythmic drug
therapy. A meta-analysis of randomized trials. Am Heart J.
158:15–20. 2009.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Pappone C, Rosanio S, Augello G, Gallus G,
Vicedomini G, Mazzone P, Gulletta S, Gugliotta F, Pappone A,
Santinelli V, et al: Mortality, morbidity, and quality of life
after circumferential pulmonary vein ablation for atrial
fibrillation: Outcomes from a controlled nonrandomized long-term
study. J Am Coll Cardiol. 42:185–197. 2003.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Nademanee K, Schwab MC, Kosar EM, Karwecki
M, Moran MD, Visessook N, Michael AD and Ngarmukos T: Clinical
outcomes of catheter substrate ablation for high-risk patients with
atrial fibrillation. J Am Coll Cardiol. 51:843–849. 2008.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Hunter RJ, McCready J, Diab I, Page SP,
Finlay M, Richmond L, French A, Earley MJ, Sporton S, Jones M, et
al: Maintenance of sinus rhythm with an ablation strategy in
patients with atrial fibrillation is associated with a lower risk
of stroke and death. Heart. 98:48–53. 2012.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Lin YJ, Chao TF, Tsao HM, Chang SL, Lo LW,
Chiang CE, Hu YF, Hsu PF, Chuang SY, Li CH, et al: Successful
catheter ablation reduces the risk of cardiovascular events in
atrial fibrillation patients with CHA2DS2-VASc risk score of 1 and
higher. Europace. 15:676–684. 2013.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Friberg L, Tabrizi F and Englund A:
Catheter ablation for atrial fibrillation is associated with lower
incidence of stroke and death: Data from Swedish health registries.
Eur Heart J. 37:2478–2487. 2016.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Saliba W, Schliamser JE, Lavi I,
Barnett-Griness O, Gronich N and Rennert G: Catheter ablation of
atrial fibrillation is associated with reduced risk of stroke and
mortality: A propensity score-matched analysis. Heart Rhythm.
14:635–642. 2017.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Cappato R, Calkins H, Chen SA, Davies W,
Iesaka Y, Kalman J, Kim YH, Klein G, Packer D and Skanes A:
Worldwide survey on the methods, efficacy, and safety of catheter
ablation for human atrial fibrillation. Circulation. 111:1100–1105.
2005.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Patel NJ, Deshmukh A, Pau D, Goyal V,
Patel SV, Patel N, Agnihotri K, Asirvatham S, Noseworthy P, Di
Biase L, Natale A and Viles-Gonzalez JF: Contemporary utilization
and safety outcomes of catheter ablation of atrial flutter in the
United States: Analysis of 89,638 procedures. Heart Rhythm.
13:1317–1325. 2016.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Sra J: Atrial fibrillation ablation
complications. J Interv Card Electrophysiol. 22:167–172.
2008.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Steinbeck G, Sinner MF, Lutz M,
Müller-Nurasyid M, Kääb S and Reinecke H: Incidence of
complications related to catheter ablation of atrial fibrillation
and atrial flutter: A nationwide in-hospital analysis of
administrative data for Germany in 2014. Eur Heart J. 39:4020–4029.
2018.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Gupta A, Perera T, Ganesan A, Sullivan T,
Lau DH, Roberts-Thomson KC, Brooks AG and Sanders P: Complications
of catheter ablation of atrial fibrillation: A systematic review.
Circ. Arrhythmia Electrophysiol. 6:1082–1088. 2013.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Prudente LA, Moorman JR, Lake D, Xiao Y,
Greebaum H, Mangrum JM, DiMarco JP and Ferguson JD: Femoral
vascular complications following catheter ablation of atrial
fibrillation. J Interv Card Electrophysiol. 26:59–64.
2009.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Sharma PS, Padala SK, Gunda S, Koneru JN
and Ellenbogen KA: Vascular complications during catheter ablation
of cardiac arrhythmias: A comparison between vascular ultrasound
guided access and conventional vascular access. J Cardiovasc
Electrophysiol. 27:1160–1166. 2016.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Edriss H, Denega T, Test V and Nugent K:
Pulmonary vein stenosis complicating radiofrequency catheter
ablation for atrial fibrillation: A literature review. Respir Med.
117:215–222. 2016.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Fender EA, Widmer RJ, Hodge DO, Cooper GM,
Monahan KH, Peterson LA, Holmes DR Jr and Packer DL: Severe
pulmonary vein stenosis resulting from ablation for atrial
fibrillation: Presentation, management, and clinical outcomes.
Circulation. 134:1812–1821. 2016.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Maclean E, Mahtani K, Roelas M, Vyas R,
Butcher C, Ahluwalia N, Honarbakhsh S, Creta A, Finlay M, Chow A,
et al: Transseptal puncture for left atrial ablation: Risk factors
for cardiac tamponade and a proposed causative classification
system. J Cardiovasc Electrophysiol. 33:1747–1755. 2022.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Sorgente A, Chierchia GB, de Asmundis C,
Sarkozy A, Capulzini L and Brugada P: Complications of atrial
fibrillation ablation: When prevention is better than cure.
Europace. 13:1526–1532. 2011.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Kumar S, Ling LH, Halloran K, Morton JB,
Spence SJ, Joseph S, Kistler PM, Sparks PB and Kalman JM:
Esophageal hematoma after atrial fibrillation ablation: Incidence,
clinical features, and sequelae of esophageal injury of a different
sort. Circ Arrhythm Electrophysiol. 5:701–705. 2012.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Mujović N, Marinković M, Lenarczyk R, Tilz
R and Potpara TS: Catheter ablation of atrial fibrillation: An
overview for clinicians. Adv Ther. 34:1897–1917. 2017.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Letsas KP, Weber R, Bürkle G, Mihas CC,
Minners J, Kalusche D and Arentz T: Pre-ablative predictors of
atrial fibrillation recurrence following pulmonary vein isolation:
The potential role of inflammation. Europace. 11:158–163.
2009.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Parkash R, Wells GA, Sapp JL, Healey JS,
Tardif JC, Greiss I, Rivard L, Roux JF, Gula L, Nault I, et al:
Effect of aggressive blood pressure control on the recurrence of
atrial fibrillation after catheter ablation: A randomized,
open-label clinical trial [SMAC-AF (substrate modification with
aggressive blood pressure control)]. Circulation. 135:1788–1798.
2017.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Pokushalov E, Romanov A, Katritsis DG,
Artyomenko S, Bayramova S, Losik D, Baranova V, Karaskov A and
Steinberg JS: Renal denervation for improving outcomes of catheter
ablation in patients with atrial fibrillation and hypertension:
Early experience. Heart Rhythm. 11:1131–1138. 2014.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Anselmino M, Matta M, D'Ascenzo F, Pappone
C, Santinelli V, Bunch TJ, Neumann T, Schilling RJ, Hunter RJ,
Noelker G, et al: Catheter ablation of atrial fibrillation in
patients with diabetes mellitus: A systematic review and
meta-analysis. Europace. 17:1518–1525. 2015.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Gorenek B, Pelliccia A, Benjamin EJ,
Boriani G, Crijns HJ, Fogel RI, Van Gelder IC, Halle M,
Kudaiberdieva G, Lane DA, et al: European heart rhythm association
(EHRA)/European association of cardiovascular prevention and
rehabilitation (EACPR) position paper on how to prevent atrial
fibrillation endorsed by the heart rhythm society (HRS) and Asia
pacific heart rhythm society (APHRS). Europace. 19:190–225.
2017.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Gu J, Liu X, Wang X, Shi H, Tan H, Zhou L,
Gu J, Jiang W and Wang Y: Beneficial effect of pioglitazone on the
outcome of catheter ablation in patients with paroxysmal atrial
fibrillation and type 2 diabetes mellitus. Europace. 13:1256–1261.
2011.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Fukamizu S, Sakurada H, Takano M, Hojo R,
Nakai M, Yuba T, Komiyama K, Tatsumoto A, Maeno K, Mizusawa Y, et
al: Effect of cigarette smoking on the risk of atrial fibrillation
recurrence after pulmonary vein isolation. J Arrhythm. 26:21–29.
2010.
|
|
106
|
Lin KJ, Cho SI, Tiwari N, Bergman M, Kizer
JR, Palma EC and Taub CC: Impact of metabolic syndrome on the risk
of atrial fibrillation recurrence after catheter ablation:
Systematic review and meta-analysis. J Interv Card Electrophysiol.
39:211–223. 2014.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Pathak RK, Middeldorp ME, Lau DH, Mehta
AB, Mahajan R, Twomey D, Alasady M, Hanley L, Antic NA, McEvoy RD,
et al: Aggressive risk factor reduction study for atrial
fibrillation and implications for the outcome of ablation: The
ARREST-AF cohort study. J Am Coll Cardiol. 64:2222–2231.
2014.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Li L, Wang ZW, Li J, Ge X, Guo LZ, Wang Y,
Guo WH, Jiang CX and Ma CS: Efficacy of catheter ablation of atrial
fibrillation in patients with obstructive sleep apnoea with and
without continuous positive airway pressure treatment: A
meta-analysis of observational studies. Europace. 16:1309–1314.
2014.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Matiello M, Nadal M, Tamborero D, Berruezo
A, Montserrat J, Embid C, Rios J, Villacastín J, Brugada J and Mont
L: Low efficacy of atrial fibrillation ablation in severe
obstructive sleep apnoea patients. Europace. 12:1084–1089.
2010.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Naruse Y, Tada H, Satoh M, Yanagihara M,
Tsuneoka H, Hirata Y, Ito Y, Kuroki K, Machino T, Yamasaki H, et
al: Concomitant obstructive sleep apnea increases the recurrence of
atrial fibrillation following radiofrequency catheter ablation of
atrial fibrillation: Clinical impact of continuous positive airway
pressure therapy. Heart Rhythm. 10:331–337. 2013.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Neilan TG, Farhad H, Dodson JA, Shah RV,
Abbasi SA, Bakker JP, Michaud GF, van der Geest R, Blankstein R,
Steigner M, et al: Effect of sleep apnea and continuous positive
airway pressure on cardiac structure and recurrence of atrial
fibrillation. J Am Heart Assoc. 2(e000421)2013.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Takigawa M, Takahashi A, Kuwahara T,
Takahashi Y, Okubo K, Nakashima E, Watari Y, Nakajima J, Yamao K,
Osaka Y, et al: Impact of alcohol consumption on the outcome of
catheter ablation in patients with paroxysmal atrial fibrillation.
J Am Heart Assoc. 5(e004149)2016.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Shah AN, Mittal S, Sichrovsky TC, Cotiga
D, Arshad A, Maleki K, Pierce WJ and Steinberg JS: Long-term
outcome following successful pulmonary vein isolation: Pattern and
prediction of very late recurrence. J Cardiovasc Electrophysiol.
19:661–667. 2008.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Suleiman M, Koestler C, Lerman A,
Lopez-Jimenez F, Herges R, Hodge D, Bradley D, Cha YM, Brady PA,
Munger TM, et al: Atorvastatin for prevention of atrial
fibrillation recurrence following pulmonary vein isolation: A
double-blind, placebo-controlled, randomized trial. Heart Rhythm.
9:172–178. 2012.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Macchia A, Grancelli H, Varini S, Nul D,
Laffaye N, Mariani J, Ferrante D, Badra R, Figal J, Ramos S, et al:
Omega-3 fatty acids for the prevention of recurrent symptomatic
atrial fibrillation: Results of the FORWARD (randomized trial to
assess efficacy of PUFA for the maintenance of sinus rhythm in
persistent atrial fibrillation) trial. J Am Coll Cardiol.
61:463–468. 2013.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Kowey PR, Reiffel JA, Ellenbogen KA,
Naccarelli GV and Pratt CM: Efficacy and safety of prescription
omega-3 fatty acids for the prevention of recurrent symptomatic
atrial fibrillation: A randomized controlled trial. JAMA.
304:2363–2372. 2010.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Kumar S, Sutherland F, Morton JB, Lee G,
Morgan J, Wong J, Eccleston DE, Voukelatos J, Garg ML and Sparks
PB: Long-term omega-3 polyunsaturated fatty acid supplementation
reduces the recurrence of persistent atrial fibrillation after
electrical cardioversion. Heart Rhythm. 9:483–491. 2012.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Nodari S, Triggiani M, Campia U, Manerba
A, Milesi G, Cesana BM, Gheorghiade M and Dei Cas L: n-3
polyunsaturated fatty acids in the prevention of atrial
fibrillation recurrences after electrical cardioversion: A
prospective, randomized study. Circulation. 124:1100–1106.
2011.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Patel D, Shaheen M, Venkatraman P,
Armaganijan L, Sanchez JE, Horton RP, Di Biase L, Mohanty P, Canby
R, Bailey SM, et al: Omega-3 polyunsaturated fatty acid
supplementation reduced atrial fibrillation recurrence after
pulmonary vein antrum isolation. Indian Pacing Electrophysiol J.
9:292–298. 2009.PubMed/NCBI
|
|
120
|
Kolandaivelu A: Role of cardiac imaging
(CT/MR) before and after RF catheter ablation in patients with
atrial fibrillation. J Atr Fibrillation. 5(523)2012.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Gimelli A, Ernst S and Liga R:
Multi-modality imaging for the identification of arrhythmogenic
substrates prior to electrophysiology studies. Front Cardiovasc
Med. 8(640087)2021.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Szili-Torok T, Kimman GJ, Scholten M,
Thornton A, Ten Cate F, Roelandt J and Jordaens L: Ablation lesions
in Koch's triangle assessed by three-dimensional myocardial
contrast echocardiography. Cardiovasc Ultrasound.
2(27)2004.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Schleberger R, Metzner A, Kuck KH,
Andresen D, Willems S, Hoffmann E, Deneke T, Eckardt L, Brachmann
J, Hochadel M, et al: Antiarrhythmic drug therapy after catheter
ablation for atrial fibrillation-Insights from the German ablation
registry. Pharmacol Res Perspect. 9(e00880)2021.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Duytschaever M, Demolder A, Phlips T,
Sarkozy A, El Haddad M, Taghji P, Knecht S, Tavernier R,
Vandekerckhove Y and De Potter T: PulmOnary vein isolation with vs
without continued antiarrhythmic drug treatment in subjects with
recurrent atrial fibrillation (POWDER AF): Results from a
multicentre randomized trial. Eur Heart J. 39:1429–1437.
2018.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Karasoy D, Gislason GH, Hansen J,
Johannessen A, Køber L, Hvidtfeldt M, Özcan C, Torp-Pedersen C and
Hansen ML: Oral anticoagulation therapy after radiofrequency
ablation of atrial fibrillation and the risk of thromboembolism and
serious bleeding: Long-term follow-up in nationwide cohort of
Denmark. Eur Heart J. 36:307–314a. 2015.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Proietti R, AlTurki A, Di Biase L, China
P, Forleo G, Corrado A, Marras E, Natale A and Themistoclakis S:
Anticoagulation after catheter ablation of atrial fibrillation: An
unnecessary evil? A systematic review and meta-analysis. J
Cardiovasc Electrophysiol. 30:468–478. 2019.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Liu XH, Xu Q, Luo T, Zhang L and Liu HJ:
Discontinuation of oral anticoagulation therapy after successful
atrial fibrillation ablation: A systematic review and meta-analysis
of prospective studies. PLoS One. 16(e0253709)2021.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Chan P, Vijan S, Morady F and Oral H:
Cost-effectiveness of left atrial catheter ablation, antiarrhythmic
therapy, and rate control therapy for paroxysmal and chronic atrial
fibrillation. Circulation. 111(e318)2005.
|
|
129
|
Eckard N, Davidson T, Walfridsson H and
Levin LÅ: Cost-effectiveness of catheter ablation for patients with
symptomatic atrial fibrillation. J Atr Fibrillation.
2(195)2009.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Winkle RA, Mead RH, Engel G, Kong MH and
Patrawala RA: Discontinuing anticoagulation following successful
atrial fibrillation ablation in patients with prior strokes. J
Interv Card Electrophysiol. 38:147–153. 2013.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Winkle RA, Mead RH, Engel G, Kong MH and
Patrawala RA: Physician-controlled costs: The choice of equipment
used for atrial fibrillation ablation. J Interv Card
Electrophysiol. 36:157–165. 2013.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Weerasooriya R, Jaïs P, Scavée C, Macle L,
Shah DC, Arentz T, Salerno JA, Raybaud F, Choi KJ, Hocini M, et al:
Dissociated pulmonary vein arrhythmia: Incidence and
characteristics. J Cardiovasc Electrophysiol. 14:1173–1179.
2003.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Vijayaraman P, Dandamudi G, Naperkowski A,
Oren J, Storm R and Ellenbogen KA: Assessment of exit block
following pulmonary vein isolation: Far-field capture masquerading
as entrance without exit block. Heart Rhythm. 9:1653–1659.
2012.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Khaykin Y, Wang X, Natale A, Wazni OM,
Skanes AC, Humphries KH, Kerr CR, Verma A and Morillo CA: Cost
comparison of ablation versus antiarrhythmic drugs as first-line
therapy for atrial fibrillation: An economic evaluation of the
RAAFT pilot study. J Cardiovasc Electrophysiol. 20:7–12.
2009.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Reynolds MR, Zimetbaum P, Josephson ME,
Ellis E, Danilov T and Cohen DJ: Cost-effectiveness of
radiofrequency catheter ablation compared with antiarrhythmic drug
therapy for paroxysmal atrial fibrillation. Circ Arrhythm
Electrophysiol. 2:362–369. 2009.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Assasi N, Blackhouse G, Xie F, Gaebel K,
Robertson D, Hopkins R, Healey J, Roy D and Goeree R: Ablation
procedures for rhythm control in patients with atrial fibrillation:
Clinical and cost-effectiveness analyses. CADTH Technol Overv.
2(e2101)2012.PubMed/NCBI
|
|
137
|
Reynolds MR, Lamotte M, Todd D, Khaykin Y,
Eggington S, Tsintzos S and Klein G: Cost-effectiveness of
cryoballoon ablation for the management of paroxysmal atrial
fibrillation. Europace. 16:652–659. 2014.PubMed/NCBI View Article : Google Scholar
|
|
138
|
McKenna C, Palmer S, Rodgers M, Chambers
D, Hawkins N, Golder S, Van Hout S, Pepper C, Todd D and Woolacott
N: Cost-effectiveness of radiofrequency catheter ablation for the
treatment of atrial fibrillation in the United Kingdom. Heart.
95:542–549. 2009.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Aronsson M, Walfridsson H, Janzon M,
Walfridsson U, Nielsen JC, Hansen PS, Johannessen A, Raatikainen P,
Hindricks G, Kongstad O, et al: The cost-effectiveness of
radiofrequency catheter ablation as first-line treatment for
paroxysmal atrial fibrillation: Results from a MANTRA-PAF substudy.
Europace. 17:48–55. 2015.PubMed/NCBI View Article : Google Scholar
|
